SAN DIEGO—(BUSINESS WIRE)—Nov. 4, 2004—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report third quarter 2004 financial results on Wednesday,November 10, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday,November 10, 2004 at 4:30 p.m. EST to discuss financial results forthe third quarter ended September 30, 2004. Uli Hacksell, Ph.D.,ACADIA's Chief Executive Officer, will also provide an update on theCompany's progress.
The conference call may be accessed by dialing 800-901-5247 forparticipants from the United States or Canada and 617-786-4501 forinternational callers (reference participant passcode 92945056). Theconference call will also be webcast live on ACADIA's website atwww.acadia-pharm.com, under the investor relations section, and willbe archived there until November 24, 2004.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizinginnovative technology to fuel drug discovery and clinical developmentof novel treatments for central nervous system disorders. ACADIAcurrently has five drug programs in clinical and preclinicaldevelopment directed at large unmet medical needs and major commercialmarkets, including Parkinson's disease, schizophrenia, chronic pain,and glaucoma. Using its proprietary drug discovery platform, ACADIAhas discovered all of the drug candidates in its product pipeline.ACADIA's corporate headquarters and biology research facilities arelocated in San Diego, California and its chemistry research facilitiesare located near Copenhagen, Denmark.
CONTACT: ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, 858-558-2871